{"name":"Cell Medica Ltd","slug":"cell-medica-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Adoptive Cellular Therapy","genericName":"Adoptive Cellular Therapy","slug":"adoptive-cellular-therapy","indication":"Other","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Best available antiviral drug therapy","genericName":"Best available antiviral drug therapy","slug":"best-available-antiviral-drug-therapy","indication":"Viral infections (specific indication not publicly disclosed)","status":"phase_3"}]}],"pipeline":[{"name":"Adoptive Cellular Therapy","genericName":"Adoptive Cellular Therapy","slug":"adoptive-cellular-therapy","phase":"phase_3","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Best available antiviral drug therapy","genericName":"Best available antiviral drug therapy","slug":"best-available-antiviral-drug-therapy","phase":"phase_3","mechanism":"This antiviral therapy works by inhibiting viral replication through direct targeting of viral enzymes or proteins essential for the virus lifecycle.","indications":["Viral infections (specific indication not publicly disclosed)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxNRlNGODdGWXdxbEN5VmdiOVhuSjZVZVJxUmlrN2xsaHdKRFF2aWgzQ205aFBaYlZ2c2VQTVJrUWRUVWplMF9rYkZqX2dNYVE4QVNWdVNwRzZUMWxSamg1V1pOMXJ2TXBidVF2U0VOME55NXp2LUF5TDNhXzNEWlVXU2IzaUF4NW83SDRoV1VCNy1LZFJxakJ2ZU9NYURPWHJmcFJuY2JKdmVJZEhhX2NCcnlUdGdWcWpTMkE?oc=5","date":"2026-03-27","type":"pipeline","source":"Healthcare Asia Magazine","summary":"IE Medica Inc wins at Healthcare Asia Pharma Awards 2026 - Healthcare Asia Magazine","headline":"IE Medica Inc wins at Healthcare Asia Pharma Awards 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxQSDBXZ243SnRELU9tTG5VZTBBaUFIQkVwVmJEYW42OGc5emVxOWVhSGlZcng5U1RDZE5IWUM5YUdYRE1VSDBpVFZxTW5iNUF0X29DSUlDa3RBaHpKRmhwODNuU1hlRmEyQzNDLU9VUlVYN29vb3dTZFl1T21FU2FWNXpGZklzS2hZQXNoV21KczXSAZYBQVVfeXFMTmdVSG5xdU5Qa2JKdFpoQWYyaHhkUkxfM1FUdmljWjc5Z2VZYkxxRzhsa0VmZWZXc2h1UWY4MFFibXlwbXplT0VBS2dITk5ya1oxVlRwN3JJUF9fOFkwQlZ5eHB1NmNwRWZQV0NvMVlmSDZka3laZlZTMjNaN1FXdWxiU0hUSC1XckpWb09qRGNVSDI3UXdR?oc=5","date":"2026-01-17","type":"pipeline","source":"BioInformant","summary":"CAR-T Cell Companies Proliferate: List of CAR-T Companies Worldwide - BioInformant","headline":"CAR-T Cell Companies Proliferate: List of CAR-T Companies Worldwide","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxONUcyZkZtLVFSSWFpdGhncGlEYXF3OVZNV0lrMzB0M1dKNlhQUHFuLXZfT1V4NGdMSnV0UC1VektMVFA0SV8wQmd1LWxFTDZlZ2FlWlVHY3hYdjlEbEtIM3ctX2NqbHdkaTBpYnUwODdVTjNPR0xjeTFjTnZZejhVMHVnQ3JRcEoyS3lOSUtlcFBhRGc?oc=5","date":"2025-11-06","type":"pipeline","source":"Insightace Analytic","summary":"Immuno-Oncology Cell Therapy Market Share, Size, Growth and Forecast to 2034 - Insightace Analytic","headline":"Immuno-Oncology Cell Therapy Market Share, Size, Growth and Forecast to 2034","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAJBVV95cUxQd2pnNl93NVIwN3dSMmpYSGNmQVMxZ2Z2SFRGSi1JN1A0aTFuWFRFRDVsN1VmT2Z1UW1WT0QzUXYwSXptQ3lIRTZ3ZDRJc3NVdnI5ZVFZQ3BSSlRHLWU2Z2RzY1Fwa3RjcGhSdERtMU1IanNqajJVRnJnd0dwMHRaRTU5MG9UR2lPeHJUODd2Nk95OWQ0Smx3bGdIc1ZCMEUtUkxxakVyY2NvU1BfZ3RWQ2xfNFpBcVRfQUVHM1Nvd2dIMWR0cTdVd0p0RHBuN3pzNkFHd3Rrc1ctTWlBVFRxcDFxLUJadUExRzkxNHJjQnZzUl9WSGZzMnBkZXFWQ2FrN0I0eHJNNnM?oc=5","date":"2025-08-14","type":"pipeline","source":"PR Newswire","summary":"Pediatric Relapsed/Refractory Neuroblastoma Market is on an Upward Trend, Driven by Innovation and Unmet Need | DelveInsight - PR Newswire","headline":"Pediatric Relapsed/Refractory Neuroblastoma Market is on an Upward Trend, Driven by Innovation and Unmet Need | DelveIns","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTFB5OXF0WWZjR0s4bXpVaGFRSlI0b2N2ZExJbnFBOTg0aHE1SW9QeHdXMzIwT05PeWZlR2VSWmNoT3NxaUJxNzRMbkE0cGlkMmF1R0FwMU5pR2pvWi1udm85Ng?oc=5","date":"2025-03-04","type":"pipeline","source":"Market.us","summary":"Bio-imaging Market Size, Share, Growth Analysis | CAGR of 14.6% - Market.us","headline":"Bio-imaging Market Size, Share, Growth Analysis | CAGR of 14.6%","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTE0wMkhCN1F4aHFrSWVHaHdwWjEwc2dTR2xVMUE0X3NoalJXNE9PQWMyUGRpSEJ0NWhLVUxIcnBZT2pfcGJaOFFVemppTU5UQXU1SUNtZnNib0JwbVlIczFmRzBKUVZpalFLSXVrSQ?oc=5","date":"2024-09-23","type":"deal","source":"팜뉴스","summary":"Nuance Pharma Announces Expansion of Bentrio License and Distribution Agreement with Altamira Therapeutics in East and South East Asia - 팜뉴스","headline":"Nuance Pharma Announces Expansion of Bentrio License and Distribution Agreement with Altamira Therapeutics in East and S","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2023-09-28","type":"pipeline","source":"PR Newswire","summary":"Neuroblastoma Market to Grow at a Substantial Growth Rate During the Forecast Period (2023-2032), Examines DelveInsight | Key Companies to Watch - Y-mAbs, Exelixis, Clarity, Eli Lilly, Innervate Radio","headline":"Neuroblastoma Market to Grow at a Substantial Growth Rate During the Forecast Period (2023-2032), Examines DelveInsight ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgJBVV95cUxOOXluekdpTUZadk43bktrb1RLNGM0LWJNMVJBZm0yQ0Z1bnE5ZGk3eUFxTjNsVUlHTGE2OW9OTWRaWEU1STBNY05CVWVaT2JDcnlZcWx2dXlPRmJpaUdySTVndV9ZV2NoYnZuZVlxY1dqRjdjc2VxcW1VX3VTRXlYcldNd1JnSWNrM3NXb05mTDdvVXBZZ2FWTmpoN2R5NTZBajJMLWdrQXc5b0tWS3RHUE9qUFpTdzBHaEpxaUlzOUNjMXFubkhDdDRSa18wcEs1MHhiRWJDallycVRSRU8xTzRsU3N4ZXgtY183cUd5NXhyUWdHVmlNbnlJcUtaVjFGWktXQkZxMWFEQlRXMXc0OXRhTlh5bXg5eDliUUdDbUp1YTB6azJRWU5B?oc=5","date":"2021-07-29","type":"deal","source":"PPF Group","summary":"Athenex agreed to acquired Kuur for $185 million adding CAR-NKT platform - PPF Group","headline":"Athenex agreed to acquired Kuur for $185 million adding CAR-NKT platform","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxPU0FKVm5neG1kRUExM3NmR3BQb3dtOUNrNzZzaldiWEhWVGdvNFhTdDFQSUFXN2hRV0pSQWFWRnY2MWFXa0JIS1VKM1FBT1ROZ1lrVW5ISUVnNWM4enRYSjE2dXJhZ0ZRZVhqem5CUml2LXNteDAxa1otMDgxR05pRE1KYmQ0SkZQN3d4M21QV1Y2M0NTQ0djaUpaSXV0UQ?oc=5","date":"2020-03-11","type":"trial","source":"Fierce Biotech","summary":"Cell Medica rebrands as Kuur, raises cash for CAR-NKT trials - Fierce Biotech","headline":"Cell Medica rebrands as Kuur, raises cash for CAR-NKT trials","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxOTjRzMm4wUU9Db2tHbzhoaVozQmRnaEZRcS1SMlRxVk9mRkNUMVNhYjJjdnQ0NlhXLTJsVWZDYjZrQk5CWXdOdlZyekpEcmhjODkxOVg3LTJaQmUwTjA5M3Z1bFNqMjBXNGFnei1GRXYxUDN2LW9uNW5La0E5QWdQdC0yWUFXcUp6ZGRqS1pwU1ZDWE4yM2Z6SEtTdWd3VVU?oc=5","date":"2020-03-11","type":"pipeline","source":"BioSpace","summary":"Cell Medica Rebrands as Kuur Therapeutics with New CEO - BioSpace","headline":"Cell Medica Rebrands as Kuur Therapeutics with New CEO","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}